Implications of Androgen-Deprivation Therapy in Patients With Prostate Cancer: A Case Study
Authors:
- Catherine C. BurkeCBCatherine C. Burke
- Susan Doyle-LindrudSDSusan Doyle-Lindrud
- 1 October 2006
- journal article
- case report
- Published by Oncology Nursing Society (ONS) in Clinical Journal of Oncology Nursing
- Vol. 10 (5) , 565-566
Abstract
S.R., a 65-year-old male with a history of prostate cancer, went to a cancer center in 2003. He had developed symptoms of bladder outlet obstruction in 1999 and was seen by a urologist. His baseline prostate-specific antigen (PSA) was 44 ng/ml. On physical examination, his prostate was enlarged, and a biopsy in January 2000 revealed adenocarcinoma with a Gleason score of 8. A metastatic workup, including a bone scan and a computed tomography scan of the abdomen and pelvis (CT A/P), was negative for evidence of metastatic disease. S.R. received conformal external beam radiation, and the luteinizing hormone-releasing hormone agonist leuprolide acetate was initiated. Following treatment, his PSA nadired to 0.2 ng/ml, and he did well until 2002, when his PSA started to rise. A reevaluation CT A/P revealed enlarged retroperitoneal and pelvic lymph nodes, and a bone scan was positive for metastatic disease. He underwent a bilateral orchiectomy in November 2002.Keywords
This publication has 10 references indexed in Scilit:
- Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatmentThe Lancet Oncology, 2006
- Managing the care of patients with bisphosphonate-associated osteonecrosisThe Journal of the American Dental Association, 2005
- Endodontic Implications of Bisphosphonate-Associated Osteonecrosis of the Jaws: A Report of Three CasesJournal of Endodontics, 2005
- Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acidUrology, 2005
- Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomyCancer, 2005
- Risk of Fracture after Androgen Deprivation for Prostate CancerNew England Journal of Medicine, 2005
- OSTEOPOROSIS AND SPINAL FRACTURES IN MEN WITH PROSTATE CANCER: RISK FACTORS AND EFFECTS OF ANDROGEN DEPRIVATION THERAPYJournal of Urology, 2004
- Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemicJournal of Oral and Maxillofacial Surgery, 2003
- A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate CarcinomaJNCI: Journal of the National Cancer Institute, 2002
- The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinomaCancer, 1998